Non-internalizing antibody-drug conjugates display potent anti-cancer activity upon proteolytic release of monomethyl auristatin E in the subendothelial extracellular matrix-Reference-Cited by-同舟云学术

Non-internalizing antibody-drug conjugates display potent anti-cancer activity upon proteolytic release of monomethyl auristatin E in the subendothelial extracellular matrix

Published:2016-12-30 Issue:7 Volume:140 Page:1670-1679
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Gébleux Rémy¹,Stringhini Marco¹,Casanova Ruben²,Soltermann Alex²,Neri Dario¹

Affiliation:

1. Department of Applied Biosciences; Swiss Federal Institute of Technology (ETH Zürich); Zürich CH-8093 Switzerland

2. Institute of Pathology, University Hospital Zurich; Zurich CH-8091 Switzerland

Funder

ETH Zürich

Swiss Federal Commission for Technology and Innovation

Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung

ERC Advanced Grant

Swiss Cancer League

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference50 articles.

1. Elucidation of the mechanism enabling tumor selective prodrug monotherapy;Bosslet;Cancer Res,1998

2. Biodistribution and radiation dosimetry of C-11-labelled docetaxel in cancer patients;Veldt;Eur J Nucl Med Mol Imag,2010

3. Toward prediction of efficacy of chemotherapy: a proof of concept study in lung cancer patients using C-11 docetaxel and Positron Emission Tomography;Veldt;Clin Cancer Res,2013

4. Small targeted cytotoxics: current state and promises from dna-encoded chemical libraries;Krall;Angew Chem Int Ed Engl,2013

5. Antibody drug-conjugates targeting the tumor vasculature: current and future developments;Gerber;MAbs,2009

Cited by 93 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antibody–drug conjugates in cancer therapy: mechanisms and clinical studies;MedComm;2024-07-28

2. Contemporary Approaches to Immunotherapy of Solid Tumors;Cancers;2024-06-19

3. Tenascin-C targeting strategies in cancer;Matrix Biology;2024-06

4. What influences the activity of Degrader−Antibody conjugates (DACs);European Journal of Medicinal Chemistry;2024-03

5. Branched pegylated linker-auristatin to control hydrophobicity for the production of homogeneous minibody-drug conjugate against HER2-positive breast cancer;Journal of Controlled Release;2024-02